Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Thyroid cancer
Stage/Subtype:  stage III papillary thyroid cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-12 of 12 for your search:
Start Over
A Study of PLX8394 as a Single Agent in Patients With Advanced, Unresectable Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PLX120-03, NCI-2015-00720, NCT02428712
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Any age
Trial IDs: SCRX001-006, NCI-2016-01071, NCT02709889
Biomarkers in Predicting Response in Patients with Locally Advanced Thyroid Cancer Receiving Vemurafenib before Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2012-0471, NCI-2012-02171, 00000363, NCT01709292
Cabozantinib-S-Malate as First-Line Therapy in Treating Patients With Radioiodine-Refractory Thyroid Cancer That is Metastatic or Cannot Be Removed By Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 28313, NCI-2014-00171, 818408, UPCC 28313, NCT02041260
Thyroid Gland Removal with or without Central Lymph Node Dissection in Treating Patients with Node Negative Thyroid Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 21 to 70
Trial IDs: UW13115, NCI-2014-00833, 2014-0391, NCT02138214
Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: KO-TIP-001, NCI-2015-01835, NCI-2015-00949, NCT02383927
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RXDX-101-02, NCI-2015-01848, NCT02568267
Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LOXO-TRK-15002, NCI-2015-01947, NCT02576431
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 3475-158, NCI-2015-02278, 163196, 2015-002067-41, NCT02628067
Pembrolizumab in Treating Patients with Metastatic or Locally Advanced Thyroid Gland Undifferentiated (Anaplastic) Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: STU 012016-019, NCI-2016-01726, NCT02688608
Questionnaire in Measuring Expectations of Patients with Thyroid Cancer Undergoing Surgery
Status: Active
Phase: No phase specified
Type: Natural history/Epidemiology, Treatment
Age: 18 and over
Trial IDs: 11-087, NCI-2016-01722, NCT01412762
Dabrafenib and Radioactive Iodine in Treating Patients With Papillary Thyroid Carcinoma
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-337, NCI-2012-00817, NCT01534897
Start Over